Wows Rome audience with live study setup and launch...
WAYLAND, Mass., March 20 /PRNewswire/ -- Tourtellotte Solutions, a global leader in bio-pharmaceutical clinical trials software, announces the launch of its Trident IWR(TM) next-generation IWR/IVRS platform for phase II-IV studies. Trident's unique parameter driven + custom pluggable design leaps ahead of legacy IVRS technologies and promises to deliver a new era of needed scalability, productivity, and ease-of-use to the straining global clinical IVRS market.
Tourtellotte representatives demonstrated the next-generation Trident IWR, fully integrated with the tcVisualize(TM) clinical supply simulator, to an appreciative audience at the VIB Clinical Supply Europe conference in Rome, Italy on February 25th, 2008.
Clinical IVRS (or IWR) systems are the source and driver of patient randomization, drug dispensing, and trial supply logistics, and as such are critical to the multi-center clinical trials that they support. Having grown up from older telephony-based technology and designs, however, current IVRS platforms are difficult to scale, and time consuming to set up. Some estimates put the industry standard programming time for a new clinical trial in IVRS to be 8-12 weeks, with commensurate cost, risk and technical design and validation overhead.
A parameter driven IWR such as Trident can eliminate this lead-time and
a host of other difficulties due to its parameterized design, coupled with
automatic 2-way integration with trial simulators such as tcVisualize. The
Tourtellotte team in Rome demonstrated this concept by soliciting a live
study design from the audience, then setting up and simulating the study in
tcVisualize, and exporting the study to Trident. After switching on the
study in Trident IWR, the TS team then acted as a clinical site to screen,
randomize, and dose subjects, and then brought the data back into
tcVisualize to show end to end study design, launch,
|SOURCE Tourtellotte Solutions|
Copyright©2008 PR Newswire.
All rights reserved